Compare Honeywell International Inc (HON) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Novo Nordisk A/S — how do they compare? Honeywell International Inc trades at $230.79 (market cap $72.93B), while Novo Nordisk A/S trades at $45.92 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.8× Honeywell International Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| HON | NVO | |
|---|---|---|
Market Cap | $72.93B | $207.85B |
Sector | Industrials | Health |
52-Week High | $248.79 | $63.98 |
52-Week Low | $188.14 | $35.29 |
Enterprise Value | $97.73B | $222.55B |
Dividend Yield | 1.22% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $242.93, down 1.32% on the day, with a bullish technical signal and strong fundamentals including a P/E of 8.85 and net income margin of 21.58%. Recent corporate actions include a 2:1 reverse stock split and consistent dividend payments. The stock shows robust earnings beats in recent quarters, though Q3 2026 results are pending.
The outlook is positive with a consensus price target of $320.54, indicating significant upside. Risks include recent growth guidance disappointments and competitive pressures in industrial automation. Analyst sentiment is predominantly buy-rated, supporting a favorable investment case amid ongoing portfolio simplification.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
